L
Leslie G. Ford
Researcher at National Institutes of Health
Publications - 90
Citations - 21684
Leslie G. Ford is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 41, co-authored 87 publications receiving 19931 citations. Previous affiliations of Leslie G. Ford include University of Texas Health Science Center at San Antonio & Walter Reed Army Institute of Research.
Papers
More filters
Journal ArticleDOI
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
Victor G. Vogel,Victor G. Vogel,Joseph P. Costantino,D. Lawrence Wickerham,Walter M. Cronin,Reena S. Cecchini,James N. Atkins,Therese B. Bevers,Louis Fehrenbacher,Eduardo R. Pajon,James L. Wade,André Robidoux,Richard G. Margolese,Joan James,Carolyn D. Runowicz,Patricia A. Ganz,Steven E. Reis,Worta McCaskill-Stevens,Leslie G. Ford,V. Craig Jordan,Norman Wolmark +20 more
TL;DR: Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxfene in preventing noninvasive disease, with far less toxicity.
Journal ArticleDOI
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
Warren B. Sateren,Edward L. Trimble,Jeffrey Abrams,Otis W. Brawley,Nancy Breen,Leslie G. Ford,Mary S. McCabe,Richard Kaplan,M Smith,Richard Ungerleider,Michaele C. Christian +10 more
TL;DR: The number of oncologists and the presence of approved cancer programs both were significantly associated with increased accrual to clinical trials, and the highest observed accruals was in suburban counties.
Journal ArticleDOI
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Jack Cuzick,Ivana Sestak,Bernardo Bonanni,Joseph P. Costantino,Steve Cummings,Andrea Decensi,Mitch Dowsett,John F. Forbes,Leslie G. Ford,Andrea Z. LaCroix,John L. Mershon,Bruce H. Mitlak,Trevor J. Powles,Umberto Veronesi,Victor G. Vogel,D. Lawrence Wickerham +15 more
TL;DR: For all SERMs, incidence of invasive oestrogen (ER)-positive breast cancer was reduced both during treatment and for at least 5 years after completion.
Journal ArticleDOI
Prevention and early detection of prostate cancer
Jack Cuzick,Mangesh A. Thorat,Gerald L. Andriole,Otis W. Brawley,Otis W. Brawley,Powel H. Brown,Zoran Culig,Rosalind A. Eeles,Leslie G. Ford,Freddie C. Hamdy,Lars Holmberg,Lars Holmberg,Dragan Ilic,Timothy J. Key,Carlo La Vecchia,Hans Lilja,Hans Lilja,Hans Lilja,Michael Marberger,Frank L. Meyskens,Lori M. Minasian,Chris Parker,Howard L. Parnes,Sven Perner,Harry G. Rittenhouse,Jack A. Schalken,Hans-Peter Schmid,Bernd J. Schmitz-Dräger,Fritz H. Schröder,Arnulf Stenzl,Bertrand Tombal,Timothy J Wilt,Alicja Wolk +32 more
TL;DR: Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment and several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer.
Journal ArticleDOI
Potential Role of Tamoxifen in Prevention of Breast Cancer
TL;DR: Randomized clinical trials of adjuvant therapy for early-stage breast cancer have demonstrated a 35% decrease in contralateral breast cancers among women receiving tamoxifen compared with controls, suggesting a potential role for tamoxIFen in chemoprevention of breast cancer in women at increased risk of the disease.